Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | The management of CAR-T toxicities in pediatric B-ALL

Sara Ghorashian • 11 Jun 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia Antibodies CAR-T Siltuximab Tocilizumab
ELIANA

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, describes toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapy in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Dr Ghorashian discusses the risks of cytokine release syndrome (CRS) as reported in the ELIANA study (NCT02435849) and the management of CRS, as well as talking on real-world data on CAR-T in B-ALL, in particular the incidence of hypogammaglobulinemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Sara Ghorashian, PhD, has received honoraria from Novartis.

More from Sara Ghorashian

Exciting updates in ALL and the value of novel immunotherapies
1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
Managing relapse after CAR-T therapy in ALL
1:20
Managing relapse after CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals